NIH Just Launched Trial To Study Allergic Reactions To Covid mRNA Vaccines

NIH Just Launched Trial To Study Allergic Reactions To Covid mRNA Vaccines

The novel coronavirus managed to change our lives for good, and the new normal is not quite the normality that we used to know. The covid vaccines have been making headlines a lot and this has been happening mostly due to their potential side effects.

Now, the NIH launched a trial to study the allergic reactions that people have to covid mRNA vaccines. 

An official press release revealed the other day that researchers from the National Institute of Allergy and Infectious Diseases (NIAID) are conducting a clinical trial designed to help understand rare but potentially serious systemic allergic reactions to covid mRNA vaccines.

According to the same official notes, the single-site trial will enroll up to 100 people aged 16 to 69 years old who had an allergic reaction to the first dose of mRNA vaccines.


It’s been also revealed that the study participants will receive a second dose of vaccine as inpatients under carefully controlled conditions at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.

“People who experienced an allergic reaction after receiving a COVID-19 mRNA vaccine may be hesitant to complete their vaccine regimen.”

This is what Anthony S. Fauci, M.D., NIAID Director said.

The controversial expert continued and said the following:

“This study will help us determine if individuals who experienced moderate systemic allergic reactions can safely receive a second dose of a COVID-19 mRNA vaccine.”

Make sure to check out the complete press release in order to learn all the available details about the subject. 

Pfizer in the news

Speaking of covid vaccines, we cannot help from bringing up Pfizer. 

Pfizer announced Wednesday it is launching a clinical trial to study the effectiveness of its antiviral pill in young children.

The treatment, as you probably know by now, is called Paxlovid, and it was authorized in December 2020 by the U.S. Food and Drug Administration for emergency use in patients aged 12 and older who have mild-to-moderate symptoms and are at increased risk of severe illness.

Rada Mateescu

Passionate about subjects from the science and health-related areas, Rada has been blogging for about ten years and at Health Thoroughfare, she's covering the latest news on these niches.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.